Meeting
2022 ASCO Annual Meeting
Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.
Authors
Geoffrey L. Uy
Washington University School of Medicine, St. Louis, MO
Geoffrey L. Uy , Vinod A. Pullarkat , Praneeth Baratam , Robert K. Stuart , Roland B. Walter , Eric S. Winer , Stefan Faderl , Vijayalakshmi Chandrasekaran , Qi Wang , Divya Chakravarthy , Ronald Cheung , Tara L. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04038437
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7031)
DOI
10.1200/JCO.2022.40.16_suppl.7031
Abstract #
7031
Poster Bd #
262
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).
First Author: Tara L. Lin
Poster
2020 ASCO Virtual Scientific Program
Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).
First Author: Tapan M. Kadia
Poster
2021 ASCO Annual Meeting
Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
First Author: Vinod Pullarkat
Poster
2022 ASCO Annual Meeting
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
First Author: James K. McCloskey